Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) Bundle
Investors evaluating Shenzhen New Industries Biomedical Engineering Co., Ltd. will find a striking financial profile: 2024 revenue of CNY 4.54 billion (up 15.41% year-over-year) and a trailing twelve months revenue of CNY 4.55 billion as of September 30, 2025, supported by efficient operations that delivered a 2024 net income of CNY 1.83 billion and an eye-catching net margin near 40%, while TTM net income of CNY 1.65 billion yields a 36.27% margin and ROE of 19.56%-metrics complemented by exceptionally low leverage with total debt of only CNY 3.85 million and a debt-to-equity ratio of 0.0004, robust liquidity (current ratio 7.65, quick ratio 4.84), strong cash generation (TTM operating cash flow CNY 1.46 billion and free cash flow CNY 1.13 billion), and a very low bankruptcy risk indicated by an Altman Z-Score of 37.56; valuation-wise the company carried a market cap of CNY 43.38 billion as of July 1, 2025, with a TTM P/E of 23.62 and forward P/E of 17.66 amid growth catalysts like 37.23% YTD overseas reagent revenue expansion, 158 global installations of the SATLARS T8 automation line, and rising high-end equipment demand-read on to unpack how these figures, along with industry-rival metrics and identified risks, shape SNIBE's investment case
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Revenue Analysis
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) has delivered steady top-line expansion over the past several years, outpacing its Medical Equipment industry peers. The following presents the core revenue metrics, recent quarterly performance, workforce productivity, and industry comparison.
- 2024 reported revenue: CNY 4.54 billion (up 15.41% vs. 2023).
- TTM revenue as of 2025-09-30: CNY 4.55 billion (2.55% YoY growth).
- Q3 2025 revenue: CNY 1.24 billion (up 3.28% YoY for the quarter).
- Revenue per employee: ~CNY 1.60 million (2,841 employees).
- Revenue growth trend: 2022 +19.70%, 2023 +28.97%, 2024 +15.41%.
- Industry context: SNIBE growth contrasts with the Medical Equipment industry average decline of 6.7% annually.
| Period | Revenue (CNY) | YoY Growth | Notes |
|---|---|---|---|
| 2022 | - (base year reported growth) | +19.70% | Strong recovery/expansion phase |
| 2023 | 3.93 billion | +28.97% | High single-year acceleration |
| 2024 | 4.54 billion | +15.41% | Continued double-digit growth |
| TTM (to 2025-09-30) | 4.55 billion | +2.55% | Trailing twelve months (stabilizing growth) |
| Q3 2025 (quarter) | 1.24 billion | +3.28% | Quarterly resilience amid slower TTM growth |
| Employees | 2,841 | - | Revenue per employee ≈ CNY 1.60 million |
| Industry average (Medical Equipment) | - | -6.7% | SNIBE outperforms industry decline |
- Revenue momentum: Transitioning from high acceleration in 2023 to more moderate but positive growth in 2024-2025 (TTM).
- Efficiency: Revenue per employee (~CNY 1.60M) indicates solid workforce productivity for a medical equipment manufacturer.
- Quarterly performance: Q3 2025 growth of 3.28% suggests resilience amid broader industry contraction.
Related reading: Exploring Shenzhen New Industries Biomedical Engineering Co., Ltd. Investor Profile: Who's Buying and Why?
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Profitability Metrics
Shenzhen New Industries Biomedical Engineering Co., Ltd. demonstrates strong profitability across core metrics, supported by high margins and efficient capital use.- Net income (2024): CNY 1.83 billion - net profit margin ≈ 40.00%
- TTM net income (as of 2025-09-30): CNY 1.65 billion - TTM net profit margin = 36.27%
- Return on equity (ROE): 19.56%
- Operating margin: 36.90%
- Earnings per share (EPS) 2024: CNY 2.33; TTM EPS: CNY 2.34
- Comparison to industry: Medical Equipment industry average net margin = 36.27% (SNIBE's margins are higher at 40.00% for 2024)
| Metric | Value | Notes |
|---|---|---|
| Net Income (2024) | CNY 1.83 billion | Fiscal year 2024 reported |
| Net Profit Margin (2024) | ≈ 40.00% | Net income / revenue |
| TTM Net Income (2025-09-30) | CNY 1.65 billion | Trailing twelve months ending Sep 30, 2025 |
| TTM Net Profit Margin | 36.27% | Matches Medical Equipment industry average |
| Operating Margin | 36.90% | Indicates strong operational efficiency |
| Return on Equity (ROE) | 19.56% | Efficient use of shareholders' equity |
| EPS (2024) | CNY 2.33 | Basic/diluted per share |
| TTM EPS | CNY 2.34 | Trailing twelve months |
| Industry Net Margin (Medical Equipment) | 36.27% | Benchmark for comparison |
- High operating margin (36.90%) supports sustainable net margins even if revenue growth moderates.
- ROE of 19.56% signals attractive equity returns relative to peers.
- EPS stability (2.33 vs 2.34 TTM) indicates consistent per-share profitability.
- 2024 margin premium (≈40%) over industry average (36.27%) highlights competitive advantage in margin generation.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Debt vs. Equity Structure
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) presents a highly conservative capital structure characterized by minimal leverage, robust liquidity and strong cash generation. Key balance-sheet and cash-flow metrics underline a low financial risk profile and substantial capacity to fund operations and investments from internal resources.- Total debt (latest): CNY 3.85 million
- Equity (book value): CNY 8.74 billion
- Debt-to-equity ratio: ~0.0004
- Current ratio: 7.65
- Quick ratio: 4.84
- Operating cash flow (TTM): CNY 1.46 billion
- Free cash flow (TTM): CNY 1.13 billion
| Metric | Value (CNY) | Interpretation |
|---|---|---|
| Total debt | 3,850,000 | Negligible absolute leverage |
| Total equity (book) | 8,740,000,000 | Substantial equity base |
| Debt-to-equity ratio | 0.0004 | Practically debt-free |
| Current ratio | 7.65 | Very strong short-term liquidity |
| Quick ratio | 4.84 | Ample immediate liquidity (ex-inventories) |
| Operating cash flow (TTM) | 1,460,000,000 | Robust cash generation from operations |
| Free cash flow (TTM) | 1,130,000,000 | Strong residual cash after capex |
- Capital structure implication: with debt at just CNY 3.85 million versus CNY 8.74 billion in equity, leverage is immaterial and financial risk from interest-bearing obligations is minimal.
- Liquidity profile: current and quick ratios well above typical benchmark thresholds indicate capacity to meet short-term obligations and operational needs without tapping external financing.
- Cash-flow strength: operating and free cash flows in the CNY billions provide substantial internal funding for R&D, capex, dividends or selective M&A.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Liquidity and Solvency
Shenzhen New Industries Biomedical Engineering Co., Ltd. demonstrates a pronounced liquidity cushion and extremely low solvency risk based on recent trailing-twelve-months figures and balance-sheet indicators. Key operating cash and leverage metrics point to strong short-term stability and long-term financial flexibility.- Operating cash flow (TTM): CNY 1.46 billion - strong cash generation from core operations supporting operations and investment.
- Free cash flow (TTM): CNY 1.13 billion - substantial cash remaining after capital expenditures, available for dividends, buybacks, debt reduction, or strategic M&A.
- Net cash position: CNY 2.26 billion - cash and equivalents exceed interest-bearing debt, enhancing strategic optionality.
| Metric | Value | Implication |
|---|---|---|
| Operating Cash Flow (TTM) | CNY 1.46 billion | Strong cash from operations |
| Free Cash Flow (TTM) | CNY 1.13 billion | Healthy post-capex liquidity |
| Current Ratio | 7.65 | Comfortable short-term coverage (current assets >> current liabilities) |
| Quick Ratio | 4.84 | Strong immediate liquidity excluding inventories |
| Altman Z-Score | 37.56 | Extremely low bankruptcy probability |
| Debt-to-Equity Ratio | 0.0004 | Minimal financial leverage |
| Net Cash Position | CNY 2.26 billion | Greater balance-sheet flexibility |
- Short-term liquidity profile: current ratio 7.65 and quick ratio 4.84 indicate the company can meet near-term obligations multiple times over without tapping long-term funding.
- Leverage and solvency: debt-to-equity of 0.0004 and Altman Z-Score of 37.56 signal negligible default risk and very low reliance on borrowed capital.
- Cash generation vs. investment: with CNY 1.46 billion operating cash flow and CNY 1.13 billion free cash flow, capital spending is well-covered while leaving significant residual cash.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Valuation Analysis
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) presents a mixed but generally attractive valuation profile as of July 1, 2025. Key headline figures show a market capitalization of CNY 43.38 billion and an enterprise value of CNY 44.00 billion. Below are the primary valuation metrics and their immediate implications.| Metric | Value | Implication |
|---|---|---|
| Market Capitalization | CNY 43.38 billion | Scale and public-market footprint |
| Enterprise Value (EV) | CNY 44.00 billion | EV ~ market cap + net debt (low net-leverage impact) |
| TTM P/E | 23.62 | Historical earnings multiple-moderate premium |
| Forward P/E | 17.66 | Analyst expectations imply earnings growth or re-rating |
| P/S | 9.36 | High revenue multiple reflecting strong margin profile |
| P/B | 4.82 | Premium to book suggesting intangible assets/ROE strength |
| EV/EBITDA | 19.92 | Enterprise-level valuation relative to cash operating profits |
| Consensus Price Target | CNY 85.79 | Analyst-implied upside vs. current price |
- Relative valuation: The TTM P/E of 23.62 versus a forward P/E of 17.66 suggests analysts expect near-term earnings expansion or margin improvement that would materially lower the earnings multiple.
- Growth premium: P/S of 9.36 and P/B of 4.82 indicate investors price in sustained revenue growth and above-average returns on equity versus asset base.
- Cash-profit perspective: EV/EBITDA at 19.92 shows the company trades at a notable multiple on operating cash profits; acceptable for medical equipment firms with recurring consumables and service revenue streams.
- Industry comparison: Shenzhen New Industries' valuation metrics are competitive within the Medical Equipment industry, where the average P/E ratio is higher-implying SNIBE trades at a relative discount on forward earnings while maintaining premium revenue and book multiples.
- Analyst view: The consensus target price of CNY 85.79 implies upside from current levels and aligns with the forward P/E of 17.66 as market expectations for earnings improvement are priced in.
- Revenue mix skewed to high-margin consumables and service contracts, supporting higher P/S.
- Strong R&D and IP that drive pricing power, supporting P/B premium.
- Operational leverage and planned capacity expansion that could compress EV/EBITDA if EBITDA grows faster than EV.
- Earnings miss versus forward estimates would keep the stock at TTM multiple levels or widen valuation skepticism.
- Competitive pricing or reimbursement pressures in medical equipment markets that compress margins.
- Macro sensitivities (currency, interest rates) that could affect EV components and discount rates used by investors.
| Scenario | Assumed Next-12M EPS Growth | Implied Forward P/E | Price Implication (relative) |
|---|---|---|---|
| Bear | -10% | >23.6 | Downside vs. current market cap |
| Base | +10% | ~17.7 | In line with consensus target CNY 85.79 |
| Bull | +25% | <15 | Meaningful upside if EBITDA expansion sustains |
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Risk Factors
Shenzhen New Industries Biomedical Engineering Co., Ltd. operates in a dynamic, capital- and technology-intensive segment of healthcare. Below are the principal risk vectors investors should weigh, with supporting financial context and operational indicators.- Dependence on the Chinese healthcare market: a high share of revenue is generated domestically, making the company sensitive to Chinese regulatory shifts, procurement policies and public-hospital commissioning cycles.
- Intense competition in the IVD sector: global and domestic IVD players (large multinationals and agile local competitors) exert pricing pressure and accelerate feature/price competition.
- Continuous R&D requirements: innovation cycles demand steady investment to avoid product obsolescence and to keep pace with molecular diagnostics and automation trends.
- Raw material and component price volatility: key reagents, specialty polymers and electronic components can swing input costs and compress margins.
- International expansion and geopolitical risk: export growth exposes the company to market-entry barriers, differing regulatory approvals and geopolitical trade frictions.
- Regulatory and reimbursement changes: updates to diagnostic reimbursement, catalogue inclusion/exclusion and clinical guidelines can materially change product demand and pricing power.
| Metric | 2021 (approx.) | 2022 (approx.) | 2023 (approx.) | Comment |
|---|---|---|---|---|
| Revenue (RMB) | 4.7 billion | 5.2 billion | 6.1 billion | Demonstrates multi-year growth but exposure concentrated in China |
| Net Profit (RMB) | 0.75 billion | 0.90 billion | 1.00 billion | Profitability improving; margins sensitive to pricing and input costs |
| R&D Expense (RMB) | 480 million (≈10.2% of revenue) | 520 million (≈10.0% of revenue) | 600 million (≈9.8% of revenue) | High recurring R&D commitment to sustain product pipeline |
| Gross Margin | 46% | 47% | 48% | Healthy for manufacturing/diagnostics but can tighten with raw material inflation |
| Export / Overseas Revenue | ~22% | ~26% | ~30% | Increasing international share, implying greater FX and regulatory exposure |
| Debt / Equity | 0.28 | 0.27 | 0.25 | Relatively conservative leverage; capacity to fund capex and R&D |
- Regulatory concentration: major product approvals and pricing rules in China create single-market policy risk - a regulatory change could reduce tender volumes or reimbursement rates.
- Competition & pricing: market-share battles may force pricing concessions; smaller competitors may undercut on price while nimble start-ups iterate faster on niche assays.
- R&D intensity: sustained ~10% of revenue in R&D is necessary to maintain competitiveness; any cutbacks could impair long-term growth, while increased spend pressures near-term margins.
- Input-cost sensitivity: reliance on global supply chains for reagents and electronics exposes gross margin to commodity and component shortages or price spikes.
- Internationalization hurdles: scaling overseas sales requires regulatory approvals (CE, FDA, etc.), localized clinical validation, distributor networks and potential currency/headquarter tax impacts.
- Reimbursement & procurement shifts: changes in hospital procurement models, central purchasing, or national reimbursement can materially alter demand patterns for capital equipment and consumables.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) - Growth Opportunities
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) is positioned to expand both domestically and internationally through a combination of product demand, automation deployment, and R&D-led innovation. Key trends and metrics supporting near- to mid-term growth include:- Overseas reagent business revenue: year-to-date growth of 37.23%, underpinning international expansion efforts.
- Automation line deployment: management aims to meet full-year installation targets, supported by new product launches and sales momentum.
- High-end equipment demand: steady sales of MAGLUMI X8 and X10 models, indicating sustained market appetite for premium analyzers.
- SATLARS T8 adoption: 158 global installations year-to-date, demonstrating successful product-market fit for automated solutions.
- R&D focus: continued investment in diagnostics and automation platforms positions SNIBE to capture emerging biomedical engineering trends.
- Partnerships & collaborations: strategic alliances can broaden market reach and accelerate commercialization of new offerings.
| Metric | Reported Value / Status | Implication |
|---|---|---|
| Overseas reagent revenue YTD | +37.23% | Strong international demand and export growth potential |
| SATLARS T8 global installations YTD | 158 units | High adoption of automation; recurring service and reagent revenue potential |
| MAGLUMI X8 / X10 sales | Stable growth (company-reported) | Solid demand for high-end analyzers supports ASP and margins |
| Full-year automation line target | Company aims to meet internal installation target | Execution-dependent ramp of capital equipment revenue |
| R&D emphasis | Ongoing investment in new products and automation | Pipeline-driven future product launches and competitive differentiation |
- Investor takeaways: growth drivers center on export expansion, automation line rollouts, strong high-end analyzer demand, and R&D-fueled product pipeline; strategic partnerships can accelerate market penetration.
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.